The UK-based AI technology company Healx has begun a partnership with the Foundation for Angelman Syndrome Therapeutics (FAST), focusing on developing new therapies for the rare neurogenetic disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback